ERBB2 and gastric cancer: In addition, HER2 targeted agents, such as trastuzumab, lapatinib, T-DM1, and pertuzumab, have all been successfully developed in breast cancer, while all these anti-HER2 agents, except for trastuzumab, failed to show clinical benefit in gastric cancer [33–36].